长沙收U换人民币|【唯一TG:@heimifeng8】|长沙USDT手续费优惠✨谷歌搜索留痕排名,史上最强SEO技术,20年谷歌SEO经验大佬✨New England Journal of Medicine: Semaglutide may halt and even reverse liver disease
Results from the ESSENCE Phase III clinical trial, published in the New England Journal of Medicine, show that treating patients with semaglutide can halt and even reverse liver disease.
The outcomes study in participants with a life-threatening form of liver disease known as steatohepatitis associated with metabolic dysfunction (MASH) was conducted at 253 clinical centers in 37 countries.
This is the first regulatory-level study demonstrating the benefit of semaglutide for people with MASH. Metabolic steatosis-related liver disease, formerly known as non-alcoholic fatty liver disease (NAFLD), is a chronic liver disease caused by excess fat in the liver. MASH is a more severe form of NAFLD.
Researchers decided to study semaglutide as a potential treatment because this class of drugs helps reduce fatty deposits and liver scarring in people with MASH.
Between May 27, 2025, and April 18, 2025, 800 participants were randomly assigned to groups that were given 2.4 milligrams of semaglutide or placebo once a week and lifestyle counseling. More than half of the participants had type 2 diabetes and about three-quarters were obese.
Results from the ESSENCE study after 72 weeks of treatment showed that 62.9% of participants experienced a reduction in steatohepatitis (inflammation of the liver with fat accumulation in the liver) compared to 34.3% of participants taking placebo. The results also show that 36.8% of patients in the semaglutide group saw an improvement in liver fibrosis compared to 22.4% in the placebo group.
The researchers also found other benefits. Patients who received semaglutide also saw improvements in liver enzymes and other measures of liver fibrosis, as well as a 10.5% weight loss. The research team will enroll about 1,200 participants from 37 countries over five years to collect data on the effects of semaglutide on long-term liver complications.